Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zivo BioscienceZIVO 8 Cash Ratio is 0.02 as of Sep. 2025, which is 71% below its 10-year median of 0.07. GuruFocus rates ZIVO with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 1,379 Biotechnology companies, Zivo Bioscience ranks worse than 98.04% on this metric.
Zivo Bioscience has a Cash Ratio of 0.02. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Zivo Bioscience's Cash Ratio or its related term are showing as below:
ZIVO'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.07 Max: 3.04
Current: 0.02
During the past 13 years, Zivo Bioscience's highest Cash Ratio was 3.04. The lowest was 0.01. And the median was 0.07.
ZIVO's Cash Ratio is ranked worse than 98.04% of 1379
companies
in the Biotechnology industry
Industry Median: 2.97
vs ZIVO: 0.02
Zivo Bioscience (OTCPK:ZIVO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Zivo Bioscience Cash Ratio Related Terms
Zivo Bioscience Cash Ratio Historical Data
* Premium members only.
The historical data trend for Zivo Bioscience's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zivo Bioscience's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zivo Bioscience Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Zivo Bioscience's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zivo Bioscience (ZIVO) has a Cash Ratio of 0.02 as of Sep. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Zivo Bioscience and its competitors. This is 71% below median its historical median of 0.07. Over the past decade, Zivo Bioscience's Cash Ratio has ranged from 0.01 to 3.04. According to the industry distribution chart, Zivo Bioscience ranks #1352 out of 1379 companies in the Biotechnology industry, placing it in the top 98%.
Is Zivo Bioscience's Cash Ratio too high?
Zivo Bioscience's current Cash Ratio of 0.02 is 71% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 3.04. The Biotechnology industry median Cash Ratio is 2.97. Zivo Bioscience's value of 0.02 is 99.3% below this industry median. Based on the distribution chart, Zivo Bioscience ranks #1352 out of 1379 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zivo Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zivo Bioscience's Cash Ratio compare to BCDA and CYCN?
According to the Biotechnology industry distribution chart, Zivo Bioscience ranks #1352 out of 1379 companies for Cash Ratio. This places Zivo Bioscience in the lower half of its industry. The industry median Cash Ratio is 2.97. Zivo Bioscience's value of 0.02 is 99.3% below this benchmark. Historically, Zivo Bioscience's own Cash Ratio has ranged from 0.01 to 3.04 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 2.97, Zivo Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.97, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zivo Bioscience's current Cash Ratio of 0.02 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Zivo Bioscience and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zivo Bioscience's current Cash Ratio is 0.02, which is 71% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zivo Bioscience stock overvalued right now?
Zivo Bioscience (ZIVO) has a current Cash Ratio of 0.02. The current Cash Ratio is 0.02, which is 71% below median its 10-year median of 0.07 and 99.3% below the Biotechnology industry median of 2.97. Zivo Bioscience's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Zivo Bioscience (ZIVO), the current Cash Ratio is 0.02 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zivo Bioscience Inc operates in one reportable segment microalgae technology. The segment is research and development operating in both the therapeutic and nutritional sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's applications are ANIMAL APPLICATIONS, HUMAN APPLICATIONS.
8GF Score
Get the complete analysis for ZIVO
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZIVO has been successfully added to your 
